Since poor-prognosis breast tumours display enhanced mitogenic signalling and increased activity of ERRα, our data imply that ERRα mediates a specific transcriptional programme in response to growth factor/RTK signalling in poor-prognosis breast tumours. The gene discussed is ESRRA; the disease is breast neoplasm.